{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:11:21Z","timestamp":1778944281255,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clgc.2026.102550","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:21:02Z","timestamp":1774311662000},"page":"102550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 study"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5504-8237","authenticated-orcid":false,"given":"Giandomenico","family":"Roviello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1856-2848","authenticated-orcid":false,"given":"Martina","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Gambale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene De Gennaro","family":"Aquino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7726-1864","authenticated-orcid":false,"given":"Eleonora","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-1419","authenticated-orcid":false,"given":"Carlo","family":"Messina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismaela Anna","family":"Vascotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Bimbatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Erbetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Messina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3665-3295","authenticated-orcid":false,"given":"Alessia","family":"Mennitto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara Elena","family":"Rebuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1261-2269","authenticated-orcid":false,"given":"Cecilia","family":"Nasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-1776","authenticated-orcid":false,"given":"Chiara","family":"Mercinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigida Anna","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9755-0567","authenticated-orcid":false,"given":"Martina","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5198-7755","authenticated-orcid":false,"given":"Mariella","family":"Sorar\u00f9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5490-672X","authenticated-orcid":false,"given":"Federico","family":"Scolari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinella Micol","family":"Mela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Salfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7743-741X","authenticated-orcid":false,"given":"Mimma","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6224-3783","authenticated-orcid":false,"given":"Valentina","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3978-040X","authenticated-orcid":false,"given":"Alessandro","family":"Rametta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Giannatempo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Cerbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0876-0226","authenticated-orcid":false,"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Doni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Pillozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2026.102550_bib0001","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2440165","article-title":"State of the art of adjuvant immunotherapy in urothelial cancer: new developments and upcoming changes","volume":"21","author":"Tassinari","year":"2025","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"10.1016\/j.clgc.2026.102550_bib0002","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41585-024-00872-0","article-title":"The evolving treatment landscape of metastatic urothelial cancer","volume":"21","author":"Roviello","year":"2024","journal-title":"Nat Rev Urol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102550_bib0003","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102550_bib0004","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.clgc.2026.102550_bib0005","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102550_bib0006","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2020.09.033","article-title":"Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index","volume":"142","author":"Buti","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2026.102550_bib0007","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejca.2021.03.041","article-title":"Predictive ability of a drug-based score in patients with advanced non\u2013small-cell lung cancer receiving first-line immunotherapy","volume":"150","author":"Buti","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2026.102550_bib0008","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejca.2022.06.002","article-title":"Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade","volume":"172","author":"Takada","year":"2022","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.clgc.2026.102550_bib0009","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2217\/imt-2023-0028","article-title":"Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab","volume":"15","author":"Taguchi","year":"2023","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.clgc.2026.102550_bib0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/CJI.0000000000000446","article-title":"Concomitant drugs prognostic score in patients with metastatic renal cell carcinoma receiving ipilimumab and nivolumab in the compassionate use program in Italy: brief communication","volume":"46","author":"Buti","year":"2023","journal-title":"J Immunother"},{"issue":"2","key":"10.1016\/j.clgc.2026.102550_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini","year":"2020","journal-title":"J Immunother cancer"},{"issue":"4","key":"10.1016\/j.clgc.2026.102550_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002421","article-title":"Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy","volume":"9","author":"Cortellini","year":"2021","journal-title":"J Immunother cancer"},{"issue":"7","key":"10.1016\/j.clgc.2026.102550_bib0013","doi-asserted-by":"crossref","first-page":"346.e1","DOI":"10.1016\/j.urolonc.2022.02.020","article-title":"Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors","volume":"40","author":"Fukuokaya","year":"2022","journal-title":"Urol Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2026.102550_bib0014","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/iju.15151","article-title":"Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab","volume":"30","author":"Tomisaki","year":"2023","journal-title":"Int J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102550_bib0015","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2081010","article-title":"Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors","volume":"11","author":"Tomita","year":"2022","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.clgc.2026.102550_bib0016","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/bco2.118","article-title":"Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma","volume":"3","author":"Okuyama","year":"2021","journal-title":"BJUI compass"},{"issue":"2","key":"10.1016\/j.clgc.2026.102550_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100090","article-title":"Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study","volume":"6","author":"Ruiz-Ba\u00f1obre","year":"2021","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.clgc.2026.102550_bib0018","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.eururo.2020.06.061","article-title":"Concomitant antibiotic use and survival in urothelial carcinoma treated with Atezolizumab","volume":"78","author":"Hopkins","year":"2020","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102550_bib0019","first-page":"834.e21","article-title":"Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma","volume":"39","author":"Ishiyama","year":"2021","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"20","key":"10.1016\/j.clgc.2026.102550_bib0020","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-20-1876","article-title":"Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with Atezolizumab","volume":"26","author":"Hopkins","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.clgc.2026.102550_bib0021","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf388","article-title":"Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25)","volume":"30","author":"Roviello","year":"2025","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.clgc.2026.102550_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008806","article-title":"Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis","volume":"12","author":"Nara","year":"2024","journal-title":"J Immunother cancer"},{"issue":"6371","key":"10.1016\/j.clgc.2026.102550_bib0023","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"6382","key":"10.1016\/j.clgc.2026.102550_bib0024","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1126\/science.aar6918","article-title":"The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies","volume":"359","author":"Zitvogel","year":"2018","journal-title":"Science"},{"issue":"7741","key":"10.1016\/j.clgc.2026.102550_bib0025","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-019-0878-z","article-title":"A defined commensal consortium elicits CD8 T cells and anti-cancer immunity","volume":"565","author":"Tanoue","year":"2019","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.clgc.2026.102550_bib0026","doi-asserted-by":"crossref","first-page":"700","DOI":"10.6004\/jnccn.2020.7647","article-title":"Association of chronic immune-mediated diarrhea and colitis with favorable cancer response","volume":"19","author":"Zou","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"19","key":"10.1016\/j.clgc.2026.102550_bib0027","doi-asserted-by":"crossref","first-page":"19530","DOI":"10.1002\/cam4.6565","article-title":"Impact of proton pump inhibitors on the onset of gastrointestinal immune-related adverse events during immunotherapy","volume":"12","author":"Lasagna","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.clgc.2026.102550_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003779","article-title":"Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy","volume":"10","author":"Jing","year":"2022","journal-title":"J Immunother cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:30:19Z","timestamp":1778941819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1558767326000509"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102550","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102550","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102550"}}